zurück

Bictegravir / emtricitabine / tenofovir alafenamide (new indication: HIV infections, patients aged between 2 and < 18 years)

 

Subject:

  • Active Substance: Bictegravir / emtricitabine / tenofovir alafenamide
  • Name: Biktarvy®
  • Therapeutic area: HIV infection
  • Pharmaceutical company: Gilead Sciences GmbH

 

Time table:

  • Start: 01.01.2023
  • Final decision by G-BA: 15.06.2023

 

Final decision:

  1. Therapy-naïve children aged 2 to < 6 years: No additional benefit proved  

  2. Therapy-naïve children aged 6 to < 12 years: No additional benefit proved

  3. Therapy-naïve adolescents aged 12 to < 18 years: No additional benefit proved

  4. Pre-treated children and adolescents aged 2 to < 18 years: No additional benefit proved